Diabetic medicine : a journal of the British Diabetic Association · 2026
Diabetes overtreatment and flags for deprescribing glucose-lowering treatment in geriatric inpatients with type 2 diabetes: Prognostic insights from a longitudinal cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Terwangne Christophe, Henrard Séverine, Marien Sophie, Steinman Michael A, Boland Benoit B, Christiaens Antoine
Аннотация
AIMS: The study investigated diabetes overtreatment (excessively intensive therapy) and flags for considering deprescribing glucose-lowering treatment (GLT) (clinical features identifying patients most likely to benefit from reducing treatment) in older adults with type 2 diabetes (T2D) and their association with five-year survival in geriatric inpatients.
METHODS: Single-centre retrospective cohort study including geriatric inpatients hospitalised between 2008 and 2015, aged ≥75 years with T2D on GLT. Diabetes overtreatment, according to the 2019-Endocrine Society guidelines, was retrospectively defined based on the patient's health status, level of HbA1c and presence of inducing hypoglycaemia GLT. Flags for deprescribing were selected from a systematic review of recommendations for GLT deprescribing in older diabetic adults.
RESULTS: Of the 447 inpatients (women: 52.8%; median age: 83 years), 89% had a poor health status, 55.2% were overtreated, and 99.5% had at least one deprescribing flag, and 44% of patients with ≥1 deprescribing flag were not overtreated. Over the five-year follow-up, median survival time after hospitalisation was 1.83 years [IQR, 1.56-2.09], with an 18% five-year survival [95%CI, 15%-22%]. Both overtreatment (HR [95%CI] 1.29 [1.04;1.58]) and accumulation of flags for deprescribing (HR [95%CI] 1.20 [1.11;1.29] per additional flag) were associated with increased mortality. Patients meeting both ≥4 flags for deprescribing and overtreated had the worst survival outcomes (10% five-year survival rate).
CONCLUSION: The cumulative burden of deprescribing flags provided complementary information beyond the current overtreatment definition. Patients classified as overtreated and combining several deprescribing criteria highlight a particularly vulnerable subgroup of patients with poor survival in which GLT use should be systematically reassessed.
METHODS: Single-centre retrospective cohort study including geriatric inpatients hospitalised between 2008 and 2015, aged ≥75 years with T2D on GLT. Diabetes overtreatment, according to the 2019-Endocrine Society guidelines, was retrospectively defined based on the patient's health status, level of HbA1c and presence of inducing hypoglycaemia GLT. Flags for deprescribing were selected from a systematic review of recommendations for GLT deprescribing in older diabetic adults.
RESULTS: Of the 447 inpatients (women: 52.8%; median age: 83 years), 89% had a poor health status, 55.2% were overtreated, and 99.5% had at least one deprescribing flag, and 44% of patients with ≥1 deprescribing flag were not overtreated. Over the five-year follow-up, median survival time after hospitalisation was 1.83 years [IQR, 1.56-2.09], with an 18% five-year survival [95%CI, 15%-22%]. Both overtreatment (HR [95%CI] 1.29 [1.04;1.58]) and accumulation of flags for deprescribing (HR [95%CI] 1.20 [1.11;1.29] per additional flag) were associated with increased mortality. Patients meeting both ≥4 flags for deprescribing and overtreated had the worst survival outcomes (10% five-year survival rate).
CONCLUSION: The cumulative burden of deprescribing flags provided complementary information beyond the current overtreatment definition. Patients classified as overtreated and combining several deprescribing criteria highlight a particularly vulnerable subgroup of patients with poor survival in which GLT use should be systematically reassessed.